THRY vs DSGN

Thryv Holdings, Inc.

(THRY) offers the better valuation at 539. 1x trailing P/E (33. 8x forward), making it the more compelling value choice. Analysts rate Thryv Holdings, Inc. (THRY) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Design Therapeutics, Inc.

(DSGN) delivered a total return of -49. 7%, compared to -86. 3% for Thryv Holdings, Inc. (THRY). Over 10 years, the gap is even starker: THRY returned -57. 5% versus DSGN's -66. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Design Therapeutics, Inc.

(DSGN) is the lower-risk stock at 1. 51β versus Thryv Holdings, Inc. 's 2. 31β — meaning THRY is approximately 52% more volatile than DSGN relative to the S&P 500. On balance sheet safety, Design Therapeutics, Inc. (DSGN) carries a lower debt/equity ratio of 0% versus 118% for Thryv Holdings, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Thryv Holdings, Inc.

grew EPS 100. 3% year-over-year, compared to -38. 6% for Design Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Thryv Holdings, Inc.

(THRY) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Design Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: THRY leads at 10. 8% versus 0. 0% for DSGN. At the gross margin level — before operating expenses — THRY leads at 64. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for THRY: 74.

7% to $6. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Design Therapeutics, Inc.

(DSGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Thryv Holdings, Inc. (THRY) carries a higher beta of 2. 31 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DSGN: -66. 0%, THRY: -57. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (THRY (Communication Services) and DSGN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.